Share
Randall Kaye
NervGen Pharma Corp., a clinical-stage biotechnology company focused on developing neuroreparative therapeutics, has appointed Randall Kaye, MD, as Chief Medical Advisor.
Dr. Kaye, who has been a member of NervGen’s Board of Directors and Chair of its Science Committee since 2020, brings extensive expertise in central nervous system (CNS) therapeutic development, regulatory strategy, and medical affairs.
This expanded role follows NervGen’s recent announcement of positive topline results from the chronic cohort of its Phase 1b/2a clinical trial of NVG-291 in individuals with cervical spinal cord injury.
In his capacity as Board member and Science Committee Chair, Dr. Kaye has been advising the NVG-291 program since its early clinical stages. He has also served as Chief Medical Officer at several biopharmaceutical companies, most recently at Longboard Pharmaceuticals Inc., where he played a key role in advancing CNS programs that led to the company’s $2.6 billion acquisition by H. Lundbeck A/S.
Dr. Kaye’s experience spans neurology, psychiatry, immunology, and infectious disease, with leadership in clinical operations, regulatory affairs, and medical strategy. He earned his MD, MPH, and BS degrees from George Washington University and completed a research fellowship at Harvard Medical School.
